

Methodological Note: Kyowa Kirin Ltd (UK and Ireland)

Kyowa Kirin Limited is committed to supporting healthcare and the development of patient care across the UK and Ireland. As such we are pleased to offer support to the organisations and practitioners central to making this happen. The support of Healthcare Organisations (HCOs) or Healthcare Practitioners (HCPs) and Other Relevant Decision Makers (ORDMs) through the provision of funds or services is essential to this. In accordance with industry regulations Kyowa Kirin Limited publishes full details about transfers of value to these individuals and organisations, annually.

The data disclosed here pertains to 'transfers of value' (TOV) where the term means a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.

TOVs are tracked for activities as defined by the relevant sections of the applicable national industry Codes (the Association of the British Pharmaceutical Industry Code of Practice and/or the Irish Pharmaceutical Healthcare Association Code of Standards).

Internal procedures are in place to capture TOVs from the following areas.

- Joint working;
- Donations, grants and benefits in kind provided to institutions, organisations and associations with regards to medical and educational goods and services;
- Contracts between Kyowa Kirin and institutions, organisations or associations of health professionals under which such institutions, organisations or associations provide any type of services for or on behalf of Kyowa Kirin conducted in line with national industry Code(s) (defined above);
- Sponsorship of attendance by health professionals and other relevant decision makers at meetings;
- Fees and expenses paid to health professionals and other relevant decision makers, or to their employers on their behalf for consultancy work conducted in line with national industry Code(s) (defined above);
- Contributions toward the costs of meetings paid to healthcare organisations or to third parties managing events on their behalf, which may include sponsorship of health professionals by way of registration fees, accommodation and/or travel.

Following collation of the above mentioned information the data set was audited in advance of publication.

The attached declaration covers the period from 1st January 2016 to 31st December 2016. These dates have been defined with relation to when the TOV was received by the HCO, HCP or ORDM.

All United Kingdom TOVs disclosed are in Pounds Sterling.

All Ireland TOVs disclosed are in Euros. Where payments were made in Euros and converted to Sterling at point of payment the sterling amount recorded has been disclosed as the TOV. Where this conversion was not made at point of payment the year end Euro rate has been used (£1 to €1.1715).

Where services were provided to an HCO by means of the provision of an individual (e.g. a pharmacist) the value of those services has been calibrated using the NHS Agenda for Change pay scale banding appropriate to that individual's training, experience and qualifications.

TOVs to HCOs have been disclosed on a per activity basis. Where more than one HCO benefits from the same TOV this has been divided accordingly. Where commercial confidentiality prevents Kyowa Kirin from identifying the HCO recipient, notably Medical Education Goods and Service items delivered to an HCO upon request to and by a third party, the TOVs have been included as an aggregated figure.

Details of HCP/ORDM TOVs have only been line listed where consent has clearly and unambiguously been granted to do so. Where consent was not given or where the individual's wishes were not clearly stated they have been included in the aggregated figures provided.

Recipients who have questions regarding their consent status or any other aspect of the Disclosure should see the Kyowa Kirin Privacy Policy Relating to Financial Disclosures.

Any general questions regarding these declarations should be directed to UK and Ireland Medical Affairs (telephone (+44 (0)1896 664000 OR medicalaffairs@kyowakirin.com).